Patritumab Deruxtecan + Platinum-based chemotherapy
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Nonsquamous Non-small Cell Lung Cancer
Conditions
Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
Trial Timeline
Jul 8, 2022 → Jun 30, 2026
NCT ID
NCT05338970About Patritumab Deruxtecan + Platinum-based chemotherapy
Patritumab Deruxtecan + Platinum-based chemotherapy is a phase 3 stage product being developed by Daiichi Sankyo for Nonsquamous Non-small Cell Lung Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05338970. Target conditions include Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05338970 | Phase 3 | Active |
Competing Products
7 competing products in Nonsquamous Non-small Cell Lung Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pemetrexed + Erlotinib + Pemetrexed + Erlotinib | Eli Lilly | Phase 2 | 52 |
| Pembrolizumab + Carboplatin + Cisplatin + Pemetrexed + Lenvatinib + Placebo matching lenvatinib | Eisai | Phase 3 | 77 |
| Pembrolizumab + Carboplatin + Cisplatin + Pemetrexed + Lenvatinib + Placebo matching lenvatinib | Eisai | Phase 3 | 77 |
| Pemetrexed | Eli Lilly | Phase 2 | 52 |
| Pembrolizumab + Pemetrexed + Carboplatin + Cisplatin + Olaparib | Merck | Phase 3 | 77 |
| Erlotinib | Roche | Pre-clinical | 23 |
| Pemetrexed + Carboplatin + demcizumab | Mereo BioPharma | Phase 2 | 44 |